Management of BCG non-responders with fixed dose intravesical gemcitabine in superficial transitional cell carcinoma of urinary bladder

Aims and Objectives: The incidence of bladder malignancy is increasing worldwide and the projected rise is 28% by 2010 for both sexes (WHO). Though intravesical adjuvant therapy with BCG is superior to any other immunotherapeutic/chemotherapeutic agent in reducing tumor recurrences and disease progr...

Full description

Bibliographic Details

Published in:	Indian Journal of Urology
Main Authors:	N K Mohanty, Rajiba L Nayak, Pawan Vasudeva, R P Arora
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2008-01-01
Subjects:	BCG gemcitabine non-responders
Online Access:	http://www.indianjurol.com/article.asp?issn=0970-1591;year=2008;volume=24;issue=1;spage=44;epage=47;aulast=Mohanty